Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor ImmunityYanping Wang(Cedars-Sinai Medical Center), Hyung L. Kim(Cedars-Sinai Medical Center)Clinical Cancer ResearchNovember 2, 202110.1158/1078-0432.ccr-21-1535Cited by 30SaveCiteExport RISWatch citationsRelated PapersA Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models|PLoS ONE|2013|62Prognostic Role of S100A8 in Human Solid Cancers: A Systematic Review and Validation|Frontiers in Oncology|2020|11Cholesterol-lowering Decreased mTOR Complex 2 Signaling and Enhanced Antitumor Immunity|medRxiv|2021|1